Biomarin Pharmaceutical (BMRN) EBITDA Margin (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of EBITDA Margin data on file, last reported at 16.92% in Q1 2026.

• Quarterly EBITDA Margin fell 1313.0% year-over-year to 16.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9.72% (down 1128.0% YoY) and the FY2025 annual result came in at 12.71%, down 425.0% from the prior year.
• EBITDA Margin climbed to 16.92% in Q1 2026, from 5.1% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 33.55% in Q2 2025 to a low of 6.02% in Q3 2025.
• A 5-year average of 11.68% and a median of 11.01% in 2023 frame the typical range for EBITDA Margin.
• Annual changes were most pronounced in 2022 — EBITDA Margin surged 2128 bps — and 2025, when it sank 2670 bps.
• Tracing BMRN's EBITDA Margin over 5 years: stood at 2.43% in 2022, then surged by 273 bps to 4.22% in 2023, then jumped by 412 bps to 21.6% in 2024, then plunged by 124 bps to 5.1% in 2025, then jumped by 432 bps to 16.92% in 2026.
• The last three EBITDA Margin figures came in at 16.92% (Q1 2026), 5.1% (Q4 2025), and 6.02% (Q3 2025), per Business Quant data.